What is Ipamorelin?
Ipamorelin was developed as a growth-hormone secretagogue. Its often-cited selectivity comes from early pharmacology experiments, not a comprehensive human safety program.
Video overview · 3:09
CJC-1295 + Ipamorelin: A Safe, Natural Growth Hormone Boost? What the Evidence Shows
What each peptide is, what the short human studies measured, why no published trial has tested the pair together, the serious adverse events FDA has noted, and their FDA and anti-doping status.
Narrated with an AI voice from this profile's sources; education only, no dosing.
Read the transcript
CJC-1295 and ipamorelin are two lab-made peptides often sold together, marketed as a safe, natural way to boost growth hormone. They do raise growth hormone in people. The rest of that claim is a different story.
CJC-1295 is a lab-made version of the hormone that tells the pituitary gland to release growth hormone. The version tested in people binds to a blood protein, so it lasts about eight days. Sellers also use the name for a version without that feature, which published human trials did not test. Ipamorelin is a five amino acid peptide that acts on the ghrelin receptor, a different trigger.
CJC-1295 signals the pituitary, ipamorelin triggers a growth-hormone pulse, and growth hormone and a related hormone, IGF-1, rise. That much has been measured. Whether it leads to more muscle, faster recovery or slower aging has not been shown. A hormone level is a lab result, not a health outcome.
In two 2006 trials in healthy adults, a single exposure to CJC-1295 raised growth hormone two- to ten-fold for six days or more. In healthy men, ipamorelin produced a single growth-hormone burst, and it cleared with a half-life of about two hours. But when ipamorelin was tested against a real medical goal, speeding recovery after bowel surgery in a hundred and fourteen patients, it did not beat placebo.
And the combination? We found no published human trial of CJC-1295 and ipamorelin used together. A 2026 review notes the pair's only muscle findings come from mice, and a 2026 sports-medicine review found that claims of better recovery and performance are not backed by human trials.
Now the safe part. The FDA says it has identified serious adverse events with CJC-1295, including a faster heart rate and a body-wide reaction that widens blood vessels. For ipamorelin, it cites a published study in which serious adverse events, including a death, were identified with intravenous use. Neither is FDA approved, both are banned in sport, and the human studies lasted weeks, so long-term safety is unknown.
So, do they raise growth hormone? Supported, in short human studies. Is the combination proven? There is no published trial. Are they natural? No: they are engineered drugs, and ipamorelin contains amino acids that do not occur in human proteins. Are they safe? Unproven. PepsRadar's claim check rates the whole claim partly supported.
The bottom line: CJC-1295 and ipamorelin raise growth hormone, but no trial shows the pair improves health, the FDA has flagged serious adverse events, and neither is approved. For the full claim check and every source, see PepsRadar dot com.
Biological role or research focus
Growth-hormone secretagogue.
Animal selectivity findings should not be read as evidence that all human uses are safe.
Role reference: Ipamorelin, the first selective growth hormone secretagogue. ↗
Names you may encounter
ipamorelin acetate
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Peptide growth-hormone secretagogue
- Main research area
- Secretagogue selectivity
- Evidence featured
- Animal / laboratory study
- Source check
- October 4, 2026
Source: Ipamorelin, the first selective growth hormone secretagogue. ↗
Quick answers
- Is Ipamorelin FDA approved?
- No. No FDA-approved drug contains Ipamorelin. Source ↗
- Is Ipamorelin safe?
- Ipamorelin is an unapproved growth-hormone secretagogue. One surgical trial found adverse events similar to placebo, but FDA notes a published report of serious events, including death, with intravenous use. Human safety data: trials only. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Ipamorelin banned in sport?
- Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S2.2.4 Growth hormone releasing factors). Source ↗
- Has the FDA taken action over Ipamorelin?
- Yes. Our records list 3 FDA actions naming it, most recently on August 24, 2026: FDA warning letter to a "research peptide" seller (Royal Peptides) naming a tesamorelin/ipamorelin blend and other peptides as unapproved new drugs. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Secretagogue pharmacology (1998) | Animal / laboratory study | Rat pituitary cells, rats, and pigs. |
| Postoperative ileus proof-of-concept trial (2014) | Human randomized trial | 117 patients enrolled after bowel resection; 114 in the safety and modified intention-to-treat populations. |
Claim check
Partly supported Are CJC-1295 and ipamorelin a safe, natural way to boost growth hormone?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Animal / laboratory study · 1998
Secretagogue pharmacology
Ipamorelin, the first selective growth hormone secretagogue.
- Population / model
- Rat pituitary cells, rats, and pigs.
- Study design
- Hormone-release and receptor-antagonist experiments with other growth-hormone secretagogues as comparators.
- Main finding
- Ipamorelin stimulated growth-hormone release. In pigs, its ACTH/cortisol response was lower than the responses seen with GHRP-2 and GHRP-6.
- Limits & context
- Selectivity in these models is not proof of endocrine safety in people. This paper did not measure human strength, recovery, body composition, or long-term harms.
Source: Ipamorelin, the first selective growth hormone secretagogue. ↗
Human randomized trial · 2014
Postoperative ileus proof-of-concept trial
Did receptor stimulation speed gastrointestinal recovery after bowel surgery?
- Population / model
- 117 patients enrolled after bowel resection; 114 in the safety and modified intention-to-treat populations.
- Study design
- Multicenter, double-blind, placebo-controlled phase 2 trial of intravenous ipamorelin during short postoperative treatment.
- Main finding
- Median time to tolerating a standardized meal was 25.3 hours with ipamorelin and 32.6 hours with placebo (p=0.15). Key and secondary efficacy analyses did not show significant between-group differences.
- How to read it
- A numerically shorter time is not the same as a demonstrated treatment effect. This trial should be retained when assessing claims about the compound.
- Limits & context
- Small proof-of-concept study with varied underlying conditions. This setting, route, and endpoint do not test muscle gain, fat loss, sleep improvement, or long-term use.
Source: Beck et al. · International Journal of Colorectal Disease · 2014 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
2 registered studies name Ipamorelin as an intervention; 0 are recruiting or under way, 0 have not started recruiting yet and 2 completed. Checked November 16, 2026 on ClinicalTrials.gov.
| Study | Status | Phase | Start | People |
|---|---|---|---|---|
| Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus NCT00672074 · Helsinn Therapeutics (U.S.), Inc | Completed | Phase 2 | 2008-04 | 117 |
| Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function NCT01280344 · Helsinn Therapeutics (U.S.), Inc | Completed | Phase 2 | 2011-04 | 320 |
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination.
Search additional PubMed records ↗Risks & interactions
Ipamorelin is an unapproved growth-hormone secretagogue. One surgical trial found adverse events similar to placebo, but FDA notes a published report of serious events, including death, with intravenous use.
Human safety data mainly come from a short phase 2 trial in 114 bowel-surgery patients, where adverse-event rates were similar to placebo. FDA found no safety data for other injectable routes.
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Serious risks
- FDA: serious adverse events including death reported in a study of intravenous ipamorelin for gut motility
- FDA: possible immune reactions (immunogenicity); unnatural amino acids complicate quality testing
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: FDA: Bulk drug substances that may present significant safety risks (category 2) ↗ · Ipamorelin for postoperative ileus: phase 2 trial (2014) ↗ · Ipamorelin, the first selective GH secretagogue (1998) ↗
Safety evidence & remaining uncertainty
FDA notes serious events in a separate intravenous study. Attribution and clinical context matter; absence of certain hormone changes in animals is not proof of human safety.
Source: FDA · Peptide compounding safety concerns ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Formerly Category 2 (FDA flagged safety risks); nominations withdrawn
Was in 503A category 2 (significant safety risks) as "Ipamorelin acetate". The nominations were withdrawn by the nominators and FDA moved it to the "nominated but withdrawn" table (page updated April 22, 2026). It is not in category 1 and is not on the 503A bulks list. It remains in 503B category 2 (outsourcing facilities) since September 29, 2023. source - World Anti-Doping Agency (2026)
- Prohibited, named on the list · S2.2.4 Growth hormone releasing factors
Named explicitly ("ipamorelin"). source
FDA actions
- FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing Ipamorelin among bulk substances that are not eligible for 503A compounding exemptions. (2020-04-01) source
- FDA warning letter to a "research peptide" seller (Royal Peptides) naming a tesamorelin/ipamorelin blend and other peptides as unapproved new drugs. (2026-08-24) source
- FDA warning letter to a "research peptide" seller (NuScience Peptides) naming a tesamorelin/ipamorelin product and other peptides as unapproved new drugs. (2026-08-24) source
Other notes
- Australia, October 2026: Victorian coroner David Ryan found that actor Richard Norton's death in March 2025 was triggered by injecting compounded CJC-1295 and ipamorelin prescribed by a doctor. Norton had told a clinic nurse he was taking double the prescribed dose. The coroner recommended the TGA review the benefits and safety risks of peptides such as CJC-1295 and ipamorelin and consider further restrictions. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & status
The foundational paper supports a pharmacological classification. It does not establish a treatment for adult muscle gain, aging, or recovery, and it did not test common seller combinations.
Source: Ipamorelin, the first selective growth hormone secretagogue. ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Mechanism & research rationale
It stimulates a growth-hormone-releasing-peptide pathway. Experiments in pigs found less ACTH/cortisol stimulation than with the comparator secretagogues.
Source: Ipamorelin, the first selective growth hormone secretagogue. ↗
Molecular structure
Questions worth asking
- What specific product, route, and research population does the claim refer to?
- Does the source measure an outcome in people, or only a laboratory marker?
- Animal selectivity findings should not be read as evidence that all human uses are safe.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Does “selective” mean free of adverse effects?
No. Selectivity describes the measured responses under specific experimental conditions.
Source: Ipamorelin, the first selective growth hormone secretagogue. ↗
Does the paper validate an ipamorelin/CJC blend?
No. A combination needs its own identity, exposure, benefit, and safety evidence.
Source: Ipamorelin, the first selective growth hormone secretagogue. ↗
What does the Postoperative ileus proof-of-concept trial study show, and what does it not?
A numerically shorter time is not the same as a demonstrated treatment effect. This trial should be retained when assessing claims about the compound. Small proof-of-concept study with varied underlying conditions. This setting, route, and endpoint do not test muscle gain, fat loss, sleep improvement, or long-term use.
Source: Beck et al. · International Journal of Colorectal Disease · 2014 ↗
References & editorial record
- FDA · Compounding safety concerns ↗
- PubMed · Animal and cell pharmacology · PMID 9849822 ↗
- Beck et al. · International Journal of Colorectal Disease · 2014 ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
PUT THE EVIDENCE IN CONTEXT
Research guides
RESEARCH FIELD GUIDE
CJC-1295 and ipamorelin: a hormone signal is only part of the story
Why GH and IGF-I measurements, product identity, and a negative postoperative trial belong in the same research discussion.
Read the guide →RESEARCH FIELD GUIDE
Are peptides legal? FDA approval, research-use labels and steroids, explained
Some peptides are FDA-approved prescription drugs; most sold online are not. What the FDA has actually said, how pharmacy compounding fits in, and why peptides are not steroids.
Read the guide →RESEARCH FIELD GUIDE
Is ipamorelin legal? Side effects, FDA status and what the studies show
Ipamorelin is not an approved drug anywhere in the US, the FDA has flagged it as a compounding safety risk, and it was left out of the 2026 HHS peptide policy. What it is, the only two human studies, the side-effect and safety concerns, and why it is banned in sport.
Read the guide →


